Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS).

× No keyword cloud information.

11 in total

1. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Authors: Hadrian Szpurka; Anna M Jankowska; Hideki Makishima; Juraj Bodo; Nelli Bejanyan; Eric D Hsi; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal: Leuk Res Date: 2010-03-23 Impact factor: 3.156

2. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Authors: Julien Broseus; Lourdes Florensa; Esther Zipperer; Susanne Schnittger; Luca Malcovati; Steven Richebourg; Eric Lippert; Jaroslav Cermak; Jyoti Evans; Morgane Mounier; José Maria Raya; François Bailly; Norbert Gattermann; Torsten Haferlach; Richard Garand; Kaoutar Allou; Carlos Besses; Ulrich Germing; Claudia Haferlach; Erica Travaglino; Elisa Luno; Maria Angeles Pinan; Leonor Arenillas; Maria Rozman; Maria Luz Perez Sirvent; Bernardine Favre; Julien Guy; Esther Alonso; Nuhri Ahwij; Andrés Jerez; Sylvie Hermouet; Marc Maynadié; Mario Cazzola; François Girodon
Journal: Haematologica Date: 2012-04-24 Impact factor: 9.941

3. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.

Authors: J M Raya; L Arenillas; A Domingo; B Bellosillo; G Gutiérrez; E Luño; M A Piñán; M Barbón; M L Pérez-Sirvent; M J Muruzábal; L Yánez; L García; A Lemes; J T Navarro; A Elosegi; M A Cortés; A Villegas; M A Durán; M Ardanaz; L Florensa
Journal: Int J Hematol Date: 2008-09-27 Impact factor: 2.490

Review 4. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors: C C Yin; L J Medeiros; C E Bueso-Ramos
Journal: Int J Lab Hematol Date: 2010-07-07 Impact factor: 2.877

5. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis.

Authors: Peter Valent; Eva Jäger; Gerlinde Mitterbauer-Hohendanner; Leonhard Müllauer; Ilse Schwarzinger; Wolfgang R Sperr; Renate Thalhammer; Friedrich Wimazal
Journal: Am J Cancer Res Date: 2010-03-16 Impact factor: 6.166

Review 6. Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors: Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544

7. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.

Authors: Dong Wook Jekarl; Sang Bong Han; Myungshin Kim; Jihyang Lim; Eun-Jee Oh; Yonggoo Kim; Hee-Je Kim; Woo-Sung Min; Kyungja Han
Journal: Korean J Hematol Date: 2010-03-31

8. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors: C Walz; N C P Cross; R A Van Etten; A Reiter
Journal: Leukemia Date: 2008-06-05 Impact factor: 11.528

Review 9. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.

Authors: A Tefferi; T Barbui
Journal: Leukemia Date: 2013-04-05 Impact factor: 11.528

Review 10. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal: Ann Hematol Date: 2007-10-16 Impact factor: 3.673